研究者詳細 - 寺井　崇二

論文 - 寺井　崇二

分割表示 1,104 件中 321 - 340 件目／全件表示 >>

Adipose most abundant 2 protein is a predictive marker for cisplatin sensitivity in cancers. 国際誌

Kenya Kamimura, Takeshi Suda, Yasuo Fukuhara, Shujiro Okuda, Yu Watanabe, Takeshi Yokoo, Akihiko Osaki, Nobuo Waguri, Toru Ishikawa, Toshihiro Sato, Yutaka Aoyagi, Masaaki Takamura, Toshifumi Wakai, Shuji Terai

Scientific reports 11 ( 1 ) 6255 - 6255 2021年3月

記述言語：英語掲載種別：研究論文（学術雑誌）

Cisplatin (CDDP) is one of the chemotherapeutic drugs being used to treat various cancers. Although effective in many cases, as high doses of CDDP cause cytotoxic effects that may worsen patients' condition, therefore, a marker of sensitivity to CDDP is necessary to enhance the safety and efficiency of CDDP administration. This study focused on adipose most abundant 2 (APM2) to examine its potential as a marker of CDDP sensitivity. The relationship of APM2 expression with the mechanisms of CDDP resistance was examined in vitro and in vivo using hepatocellular carcinoma (HCC) cells, tissues and serum of HCC patients (n = 71) treated initially with intrahepatic arterial infusion of CDDP followed by surgical resection. The predictability of serum APM2 for CDDP sensitivity was assessed in additional 54 HCC patients and 14 gastric cancer (GC) patients. APM2 expression in CDDP-resistant HCC was significantly higher both in serum and the tissue. Bioinformatic analyses and histological analyses demonstrated upregulation of ERCC6L (DNA excision repair protein ERCC6-like) by APM2, which accounts for the degree of APM2 expression. The serum APM2 level and chemosensitivity for CDDP were assessed and cut-off value of serum APM2 for predicting the sensitivity to CDDP was determined to be 18.7 µg/mL. The value was assessed in HCC (n = 54) and GC (n = 14) patients for its predictability of CDDP sensitivity, resulted in predictive value of 77.3% and 100%, respectively. Our study demonstrated that APM2 expression is related to CDDP sensitivity and serum APM2 can be an effective biomarker of HCC and GC for determining the sensitivity to CDDP.Trial registration: This study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN000028487).

DOI： 10.1038/s41598-021-85498-7

PubMed

researchmap

Relationship between detection of hepatitis B virus in saliva and periodontal disease in hepatitis B virus carriers in Japan. 国際誌

Hiroteru Kamimura, Jun Watanabe, Tomoyuki Sugano, Junji Kohisa, Hiroyuki Abe, Kenya Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Shogo Okoshi, Yoshinari Tanabe, Ritsuo Takagi, Hirofumi Nonaka, Shuji Terai

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 27 ( 3 ) 492 - 496 2021年3月

記述言語：英語掲載種別：研究論文（学術雑誌）

INTRODUCTION: Although hepatitis B virus infection is well-described, the additional risk posed by oral bleeding in individuals with chronic hepatitis B virus infection has not been determined. This study aimed to determine the quantity of hepatitis B virus in the saliva of carriers in Japan, as a means of understanding the potential risk for horizontal transmission. METHODS: Saliva samples from 48 confirmed hepatitis B virus carriers were included in the analysis. Hepatitis B virus concentrations and the presence of occult blood as periodontal disease were evaluated in each sample. RESULTS: Hepatitis B surface antigen was identified in 46 of the 48 samples (98%), with hepatitis B virus DNA identified in 19 of the 48 saliva samples (40%). Occult blood was detected in 32 (67%) samples with the prevalence increasing as a function of age (r = 0.413; P = 0.003). There was a significantly positive correlation between hepatitis B virus DNA levels in the serum and saliva specimens (r = 0.895; P < 0.001). CONCLUSIONS: Occult blood in saliva was detected in most participants. The detection of hepatitis B virus DNA correlated positively with hepatitis B virus in the serum and occult blood in the saliva. Therefore, improved care of periodontal disease among older people is important for preventing horizontal transmission of hepatitis B virus.

DOI： 10.1016/j.jiac.2020.10.028

PubMed

researchmap

Evaluation of intestinal microbiota, short-chain fatty acids, and immunoglobulin a in diversion colitis. 国際誌

Kentaro Tominaga, Atsunori Tsuchiya, Takeshi Mizusawa, Asami Matsumoto, Ayaka Minemura, Kentaro Oka, Motomichi Takahashi, Tomoaki Yosida, Yuzo Kawata, Kazuya Takahashi, Hiroki Sato, Satoshi Ikarashi, Kazunao Hayashi, Ken-Ichi Mizuno, Yosuke Tajima, Masato Nakano, Yoshifumi Shimada, Hitoshi Kameyama, Junji Yokoyama, Toshifumi Wakai, Shuji Terai

Biochemistry and biophysics reports 25 100892 - 100892 2021年3月

記述言語：英語掲載種別：研究論文（学術雑誌）

It is reported that an increase in aerobic bacteria, a lack of short-chain fatty acids (SCFAs), and immune disorders in the diverted colon are major causes of diversion colitis. However, the precise pathogenesis of this condition remains unclear. The aim of the present study was to examine the microbiota, intestinal SCFAs, and immunoglobulin A (IgA) in the diverted colon. Eight patients underwent operative procedures for colostomies. We assessed the diverted colon using endoscopy and obtained intestinal samples from the diverted colon and oral colon in these patients. We analyzed the microbiota and SCFAs of the intestinal samples. The bacterial communities were investigated using a 16S rRNA gene sequencing method. The microbiota demonstrated a change in the proportion of some species, especially Lactobacillus, which significantly decreased in the diverted colon at the genus level. We also showed that intestinal SCFA values were significantly decreased in the diverted colon. Furthermore, intestinal IgA levels were significantly increased in the diverted colon. This study was the first to show that intestinal SCFAs were significantly decreased and intestinal IgA was significantly increased in the diverted colon. Our data suggest that SCFAs affect the microbiota and may play an immunological role in diversion colitis.

DOI： 10.1016/j.bbrep.2020.100892

PubMed

researchmap

Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database.

Shuji Terai, Amy Buchanan-Hughes, Alvin Ng, I-Heng Lee, Ken Hasegawa

Journal of gastroenterology 56 ( 3 ) 274 - 284 2021年3月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: This study examined demographics, comorbidities and healthcare resource use (HCRU) and costs among Japanese patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). METHODS: We conducted a repeated cross-sectional analysis of the Medical Data Vision (MDV) claims database, from January 2011 to March 2018. Demographics were described at index date and by calendar year; a "NASH" subpopulation included patients with ≥ 1 claim for NASH at any time. Prevalence of pre-specified comorbidities of interest and data-emergent top comorbidities were estimated. All-cause HCRU and costs were quantified by calendar year. Outcomes were compared between 2011 and 2017 using partially overlapping t tests. RESULTS: 58,958 patients (mean age 61.6 years; 55.5% male) were included. 1139 patients (2%) were in the NASH subpopulation. At baseline, comorbid cardiovascular disease (69.4%), diabetes (62.1%) and hyperlipidaemia (54.4%) were most prevalent; comorbidity prevalence increased with age. Mean outpatient visits decreased from 9.36 per patient in 2011 to 7.80 in 2017; mean inpatient admissions increased (both p < 0.001 for 2011 vs 2017). Mean total all-cause healthcare costs ranged from \322,206 to \340,399 per patient per year between 2011 and 2017. Although total all-cause healthcare costs did not change significantly (p = 0.552), cost burden shifted from the outpatient to inpatient setting between 2011 and 2017. All-cause healthcare resource use/costs were generally higher for the NASH subgroup compared with the overall population. CONCLUSIONS: There is a high burden of disease among Japanese NAFLD/NASH patients, including a high prevalence of comorbidities which generally increase with age. Accordingly, substantial all-cause HCRU and costs were incurred.

DOI： 10.1007/s00535-021-01759-2

PubMed

researchmap

当院における肝炎医療コーディネーターの取り組み・課題と今後の展望

廣川光, 荒生祥尚, 薛徹, 寺井崇二

日本消化器病学会雑誌 118 ( 臨増総会 ) A266 - A266 2021年3月

Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan

Ryosuke Tateishi, Takeshi Matsumura, Takeshi Okanoue, Toshihide Shima, Koji Uchino, Naoto Fujiwara, Takafumi Senokuchi, Kazuyoshi Kon, Takayoshi Sasako, Makiko Taniai, Takumi Kawaguchi, Hiroshi Inoue, Hirotaka Watada, Naoto Kubota, Hitoshi Shimano, Shuichi Kaneko, Etsuko Hashimoto, Sumio Watanabe, Goshi Shiota, Kohjiro Ueki, Kosuke Kashiwabara, Yutaka Matsuyama, Hideo Tanaka, Masato Kasuga, Eiichi Araki, Kazuhiko Koike, Yoshiyasu Karino, Shuhei Hige, Masatomo Sekiguchi, Koji Ogawa, Hideaki Miyoshi, Kyu Yong Cho, Masaru Baba, Atsushi Inoue, Kazuobu Aso, Mitsuyoshi Okada, Yasuhiro Takikawa, Kei Endo, Yasushi Ishigaki, Hirobumi Togashi, Michiaki Unno, Takanori Morikawa, Hideki Katagiri, Shojiro Sawada, Hiromasa Ohira, Atsushi Takahashi, Michio Shimabukuro, Akihiro Kudo, Naomi Tanaka, Junko Mitsuhashi, Toshifumi Tokai, Yasushi Matsuzaki, Tadashi Ikegami, Masato Imai, Kou Nishikawa, Sadao Takahashi, Sumiko Nagoshi, Kosuke Maezawa, Masafumi Matsuda, Tetsuhiro Chiba, Masayuki Yokoyama, Koutaro Yokote, Yoko Hidetaka, Mitsuhiko Moriyama, Hitomi Nakamura, Midori Fujishiro, Tadakazu Hisamatsu, Kaori Nishikawa, Toshihiko Nouchi, Yuki Sakurai, Harumi Daikoku, Michinori Murayama, Yoshinori Saigusa, Takashi Matsui, Ryosuke Tateishi, Hidenari Nagai, Takanori Mukozu, Takahisa Hirose, Masahiko Miyagi, Hiroaki Sato, Akira Mizuki, Masanori Miura, Yuzuru Sato, Rena Kaneko, Kumiko Hamano, Hiroko Kato, Kentaro Kikuchi, Yusuke Kajiyama, Makoto Chuma, Hiroko Ito, Hiroshi Yasuda, Nobuyuki Matsumoto, Yasushi Tanaka, Yoshio Nagai, Kento Imajo, Yasuo Terauchi, Yuzuru Ito, Shuji Terai, Hirohito Sone, Satoshi Matsunaga

Journal of Gastroenterology 56 ( 3 ) 261 - 273 2021年3月

掲載種別：研究論文（学術雑誌）

Background: Although type 2 diabetes mellitus (T2DM) is a known risk factor for hepatocellular carcinoma (HCC) development, the annual incidence in diabetes patients is far below the threshold of efficient surveillance. This study aimed to elucidate the risk factors for HCC in diabetic patients and to determine the best criteria to identify surveillance candidates. Methods: The study included 239 patients with T2DM who were diagnosed with non-viral HCC between 2010 and 2015, with ≥ 5 years of follow-up at diabetes clinics of 81 teaching hospitals in Japan before HCC diagnosis, and 3277 non-HCC T2DM patients from a prospective cohort study, as controls. Clinical data at the time of and 5 years before HCC diagnosis were collected. Results: The mean patient age at HCC diagnosis was approximately 73 years, and 80% of the patients were male. The proportion of patients with insulin use increased, whereas the body mass index (BMI), proportion of patients with fatty liver, fasting glucose levels, and hemoglobin A1c (HbA1c) levels decreased significantly in 5 years. In the cohort study, 18 patients developed HCC during the mean follow-up period of 4.7 years with an annual incidence of 0.11%. Multivariate logistic regression analyses showed that the FIB-4 index was an outstanding predictor of HCC development along with male sex, presence of hypertension, lower HbA1c and albumin levels, and higher BMI and gamma-glutamyl transpeptidase levels. Receiver-operating characteristic analyses showed that a FIB-4 cut-off value of 3.61 could help identify high-risk patients, with a corresponding annual HCC incidence rate of 1.1%. Conclusion: A simple calculation of the FIB-4 index in diabetes clinics can be the first step toward surveillance of HCC with a non-viral etiology.

DOI： 10.1007/s00535-020-01754-z

Scopus

PubMed

researchmap

門脈圧亢進症:診断と治療の最前線傍食道静脈の発達の有無を指標としたEVL/EISの選択による治療成績

薛徹, 横山純二, 寺井崇二

日本消化器病学会雑誌 118 ( 臨増総会 ) A201 - A201 2021年3月

地域病院健診時の消化器サルコペニア疾患診療の有用性

上村博輝, 小島雄一, 寺井崇二

日本消化器病学会雑誌 118 ( 臨増総会 ) A345 - A345 2021年3月

【小児期発症慢性肝疾患における移行期医療の現状と課題-小児と成人のダイアログ-】NAFLD Pediatric fatty liver disease(PeFLD)における概説と成人との比較(肝組織学的検討を含めて) 小児と成人の相違

上村博輝, 山崎文紗子, 佐藤毅昂, 薛徹, 土屋淳紀, 上村顕也, 高村昌昭, 寺井崇二, 長崎啓祐, 斎藤昭彦, 梅津哉

肝胆膵 82 ( 3 ) 425 - 440 2021年3月

消化器疾患診療におけるディープラーニングの有用性の検証

上村博輝, 野中尋史, 寺井崇二

日本消化器病学会雑誌 118 ( 臨増総会 ) A354 - A354 2021年3月

消化器疾患と神経系の臓器相関脂肪性肝疾患における自律神経系ネットワークを介したセロトニンの関与

大脇崇史, 上村顕也, 寺井崇二

日本消化器病学会雑誌 118 ( 臨増総会 ) A144 - A144 2021年3月

肝発癌抑制を目指したB型肝炎の最新治療肝細胞癌におけるYAPとHBx蛋白の臨床的有用性の検討

小田知友美, 上村顕也, 寺井崇二

日本消化器病学会雑誌 118 ( 臨増総会 ) A73 - A73 2021年3月

消化器領域におけるバイオマーカーの新展開エクソソームタンパクEps8の膵癌バイオマーカーとしての検討

林和直, 土屋淳紀, 寺井崇二

日本消化器病学会雑誌 118 ( 臨増総会 ) A151 - A151 2021年3月

消化器領域における再生医療:基礎的研究の最前線 HMGB1の部分ペプチドを用いた新たな肝硬変治療開発

土屋淳紀, 野尻俊介, 寺井崇二

日本消化器病学会雑誌 118 ( 臨増総会 ) A132 - A132 2021年3月

ACLF:欧米、アジアと我が国での差異 Acute on chronic liver failureに対する肝細胞老化改善の検証

渡邉雄介, 土屋淳紀, 寺井崇二

日本消化器病学会雑誌 118 ( 臨増総会 ) A110 - A110 2021年3月

胆膵疾患研究の最前線〜from bench to bedside, from bedside to bench〜膵臓選択的ハイドロダイナミック遺伝子導入法による新規膵癌モデル動物の確立

柴田理, 上村顕也, 寺井崇二

日本消化器病学会雑誌 118 ( 臨増総会 ) A232 - A232 2021年3月

脂肪性肝疾患:新規治療法を目指した基礎研究とトランスレーショナルリサーチ ONO-1301を用いた肝硬変に対するセルフリー治療の開発

茂木聡子, 土屋淳紀, 寺井崇二

日本消化器病学会雑誌 118 ( 臨増総会 ) A223 - A223 2021年3月

消化器領域の救急医療、集中治療:急性膵炎予後因子・CT gradeを用いた重症急性膵炎の予後・感染性被包化膵壊死合併の予測

林和直, 五十嵐聡, 寺井崇二

日本消化器病学会雑誌 118 ( 臨増総会 ) A251 - A251 2021年3月

高齢者膵癌に対する治療の適応と限界県全域における高齢者膵癌診療の現状多施設後方視的研究の結果より

五十嵐聡, 林和直, 寺井崇二

日本消化器病学会雑誌 118 ( 臨増総会 ) A237 - A237 2021年3月

Potential Effect of a Selective Peroxisome Proliferator-activated Receptor Alpha Modulator on Metabolic Dysfunction-associated Fatty Liver Disease.

Hiroteru Kamimura, Atsushi Kimura, Shuji Terai

Internal medicine (Tokyo, Japan) 60 ( 14 ) 2165 - 2166 2021年2月

　前のページ - 次のページ　

<寺井 崇二>

論文 - 寺井 崇二

<寺井　崇二>

論文 - 寺井　崇二